Alkermes plc. 4

Craig C. Hopkinson, EVP R&D and Chief Medical Officer of Alkermes plc, exercised 5,000 stock options and sold 9,000 ordinary shares on 2026-09-01 under a Rule 10b5-1 plan.

On September 1, 2026, Alkermes plc EVP R&D and Chief Medical Officer Craig C. Hopkinson exercised 5,000 employee stock options with a $24.59 strike price and simultaneously sold 9,000 ordinary shares at a weighted average price of $46.986 pursuant to a Rule 10b5-1 trading plan, resulting in a net decrease in his direct holdings to 61,276 ordinary shares. The option exercise, which was fully vested and non‑cash (zero reported exercise price in the derivative line), generated approximately $122,950 of intrinsic value, while the related open‑market sale totaled roughly $422,874 in proceeds; post‑transaction, his remaining stake is valued at about $2.88 million using the reported sale price as a proxy for market value. Overall, the filing reflects a routine, pre‑planned combination of option exercise and partial share sale rather than a straightforward discretionary purchase or sale of common stock.

Filing Facts

CIK

1520262

Ticker

ALKS

Form

4

Source Type

fda

Accession

0001520262-26-000118

Alert Tier

6